1. Home
  2. BCYC

as of 08-03-2026 4:00pm EST

$3.87
+$0.01
+0.26%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.

Founded: 2009 Country:
United Kingdom
United Kingdom
Employees: N/A City: CAMBRIDGE
Market Cap: 291.8M IPO Year: 2019
Target Price: $13.90 AVG Volume (30 days): 335.4K
Analyst Decision: Buy Number of Analysts: 10
Dividend Yield:
N/A
Dividend Payout Frequency: quarterly
EPS: -1.59 EPS Growth: -8.97
52 Week Low/High: $3.80 - $9.16 Next Earning Date: 04-30-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): -53.41% Revenue Growth (next year): -25.97%
P/E Ratio: -2.43 Index: N/A
Free Cash Flow: -252025000.0 FCF Growth: N/A

AI-Powered BCYC Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 21 hours ago

AI Recommendation

hold
Model Accuracy: 75.69%
75.69%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Bicycle Therapeutics plc (BCYC)

Skynner Michael

CHIEF SCIENTIFIC OFFICER

Sell
BCYC Jul 6, 2026

Avg Cost/Share

$4.31

Shares

532

Total Value

$2,292.92

Owned After

157,171

SEC Form 4

Hannay Michael Charles Ferguson

CHIEF PROD & SUPPLY CHAIN OFF

Sell
BCYC Jul 6, 2026

Avg Cost/Share

$4.31

Shares

255

Total Value

$1,099.05

Owned After

94,375

SEC Form 4

Thompson Travis Alvin

Chief Financial Officer

Sell
BCYC Jul 6, 2026

Avg Cost/Share

$4.31

Shares

104

Total Value

$448.24

Owned After

64,441

SEC Form 4

Lee Kevin

CHIEF EXECUTIVE OFFICER

Sell
BCYC Jul 6, 2026

Avg Cost/Share

$4.31

Shares

1,737

Total Value

$7,486.47

Owned After

603,671

SEC Form 4

Perry Jennifer Scott

Chief Operating Officer

Sell
BCYC Jul 6, 2026

Avg Cost/Share

$4.32

Shares

376

Total Value

$1,630.55

Owned After

91,385

Skynner Michael

CHIEF SCIENTIFIC OFFICER

Sell
BCYC Jul 2, 2026

Avg Cost/Share

$4.27

Shares

1,859

Total Value

$7,937.93

Owned After

157,171

SEC Form 4

Hannay Michael Charles Ferguson

CHIEF PROD & SUPPLY CHAIN OFF

Sell
BCYC Jul 2, 2026

Avg Cost/Share

$4.27

Shares

1,506

Total Value

$6,430.62

Owned After

94,375

SEC Form 4

Thompson Travis Alvin

Chief Financial Officer

Sell
BCYC Jul 2, 2026

Avg Cost/Share

$4.27

Shares

819

Total Value

$3,497.13

Owned After

64,441

SEC Form 4

Lee Kevin

CHIEF EXECUTIVE OFFICER

Sell
BCYC Jul 2, 2026

Avg Cost/Share

$4.27

Shares

5,905

Total Value

$25,214.35

Owned After

603,671

SEC Form 4

Perry Jennifer Scott

Chief Operating Officer

Sell
BCYC Jul 2, 2026

Avg Cost/Share

$4.27

Shares

1,036

Total Value

$4,423.72

Owned After

91,385

SEC Form 4

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q2

Q2 2026 Earnings

8-K BUY

Jul 30, 2026 · 100% conf.

AI Prediction BUY

1D

+0.81%

$4.04

Act: -3.74%

5D

+9.31%

$4.38

20D

+8.22%

$4.34

Price: $4.01 Prob +5D: 100% AUC: 1.000
0001104659-26-088455

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.e618d017.1785591281.2ff1f168

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

2026
Q1

Q1 2026 Earnings

8-K BUY

Apr 30, 2026 · 100% conf.

AI Prediction BUY

1D

+0.74%

$4.76

Act: +1.17%

5D

+10.45%

$5.21

Act: +3.60%

20D

+9.95%

$5.19

Act: -0.42%

Price: $4.72 Prob +5D: 100% AUC: 1.000
0001104659-26-052107

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.c706d217.1784333530.cc9f7d96

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

2025
Q4

Q4 2025 Earnings

8-K SELL

Mar 17, 2026 · 100% conf.

AI Prediction SELL

1D

-0.54%

$5.10

Act: -7.30%

5D

-7.71%

$4.73

20D

-9.61%

$4.64

Price: $5.13 Prob +5D: 0% AUC: 1.000
0001104659-26-028954

false 0001761612 X0 00-0000000 true

0001761612

2026-03-17 2026-03-17

0001761612

us-gaap:CommonStockMember

2026-03-17 2026-03-17

0001761612

bcyc:AmericanDepositarySharesMember

2026-03-17 2026-03-17

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

March 17, 2026

Date of Report (Date of earliest event reported)

Bicycle Therapeutics plc

(Exact name of registrant as specified in its charter)

England and Wales

001-38916

Not applicable

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

Blocks A & B, Portway Building, Granta Park Great Abington, Cambridge

United Kingdom

CB21

6GS

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: +44 1223 261503

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol (s) Name of each exchange on which registered

Ordinary shares, nominal value £0.01 per share n/a The Nasdaq Stock Market LLC*

American Depositary Shares, each representing one ordinary share, nominal value £0.01 per share

BCYC

The Nasdaq Stock Market LLC

* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02. Results of Operations and Financial Condition

On March 17, 2026, Bicycle Therapeutics plc (the “Company”) issued a press release announcing financial results for the fiscal quarter and the year ended December 31, 2025 and other business highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers

On March 11, 2026, the Company’s Board of Directors appointed Jennifer Perry, Pharm.D. as Chief Operating Officer, effective as of March 17, 2026 (the “Transition Date”). Dr. Perry will succeed Alistair Milnes, who will serve as the Company’s Chief Corporate Development Officer, effective as of the Transition Date.

Prior to her appointment as Chief Operating Officer, Dr. Perry, age 52, served as the Company’s Chief Strategy Officer and Head of Commercial, a role she held since July 2024. Dr. Perry previously served as the Company’s Senior Vice President, Commercial, from April 2023 to July 2024, and as the Company’s Vice President, Global Scientific Engagement and Medical Affairs from August 2022 to April 2023. Dr. Perry has over 20 years of experience in the biotech and pharmaceutical industries, with 15 years in oncology. Prior to joining the Company, from August 2020 to August 2022, Dr. Perry served as Vice President, Hematology Oncology Sales at TG Therapeutics, Inc. and previously served as Vice President, US Oncology Sales at GSK/Tesaro from July 2019 to August 2020. Dr. Perry attended Loyola University Chicago for her undergraduate education before earning her Pharm.D. from the University of Illinois Chicago.

In connection with her appointment as Chief Operating Officer, Dr. Perry’s will receive a base salary of $550,000 and will be eligible to receive a target annual cash performance bonus of 50% of her base salary

Share on Social Networks: